Evidence map›Paper›PMID 39318062›Full record

ArticleProteomics2024

Development of a Proteomic Workflow for the Identification of Heparan Sulphate Proteoglycan-Binding Substrates of ADAM17.

Matteo Calligaris, Donatella Pia Spanò, Maria Chiara Puccio, Stephan A Müller, Simone Bonelli, Margot Lo Pinto, Giovanni Zito, Carl P Blobel, Stefan F Lichtenthaler, Linda Troeberg and 1 more

Abstract read
In one paragraph

Article in Proteomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Matteo CalligarisDepartment of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, Palermo, Italy.
Donatella Pia SpanòDepartment of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, Palermo, Italy.
Maria Chiara PuccioDepartment of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, Palermo, Italy.
Stephan A MüllerNeuroproteomics Department, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Simone BonelliDepartment of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, Palermo, Italy.
Margot Lo PintoDepartment of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, Palermo, Italy.
Giovanni ZitoDepartment of Research, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Palermo, Italy.
Carl P BlobelArthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, USA.
Stefan F LichtenthalerNeuroproteomics Department, German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Linda TroebergNorwich Medical School, University of East Anglia, Norwich, UK.
Simone Dario ScilabraDepartment of Research IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Proteomics Group of Ri.MED Foundation, Palermo, Italy.ORCID 0000-0001-7300-6153

Funding

Role of iRhoms and ADAM17 in EGFR and TNFalpha signalingR35GM134907 · NIGMS · HOSPITAL FOR SPECIAL SURGERY · PI BLOBEL, CARL PETER · 2020 to 2024
$2.0M
CLINSPECT-M (FKZ161L0214C)Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)Munich Cluster for Systems Neurology EXC 2145 SyNergy- ID 390857198National Recovery and Resilience Plan M4C2, part of the NextGenerationEU Programme, granted by the European Union for the Research Programme "National Biodiversity Future Center - NBFC" CN_00000033(CN5-Spoke6)-CUPB73C21001300006NIGMS NIH HHS R35 GM134907
6 · The paper itself

Abstract

Ectodomain shedding, which is the proteolytic release of transmembrane proteins from the cell surface, is crucial for cell-to-cell communication and other biological processes. The metalloproteinase ADAM17 mediates ectodomain shedding of over 50 transmembrane proteins ranging from cytokines and growth factors, such as TNF and EGFR ligands, to signalling receptors and adhesion molecules. Yet, the ADAM17 sheddome is only partly defined and biological functions of the protease have not been fully characterized. Some ADAM17 substrates (e.g., HB-EGF) are known to bind to heparan sulphate proteoglycans (HSPG), and we hypothesised that such substrates would be under-represented in traditional secretome analyses, due to their binding to cell surface or pericellular HSPGs. Thus, to identify novel HSPG-binding ADAM17 substrates, we developed a proteomic workflow that involves addition of heparin to solubilize HSPG-binding proteins from the cell layer, thereby allowing their mass spectrometry detection by heparin-treated secretome (HEP-SEC) analysis. Applying this methodology to murine embryonic fibroblasts stimulated with an ADAM17 activator enabled us to identify 47 transmembrane proteins that were shed in response to ADAM17 activation. This included known HSPG-binding ADAM17 substrates (i.e., HB-EGF, CX3CL1) and 14 novel HSPG-binding putative ADAM17 substrates. Two of these, MHC-I and IL1RL1, were validated as ADAM17 substrates by immunoblotting.

Indexed as

ADAM17 ProteinHeparan Sulfate ProteoglycansProteomicsAnimalsFibroblastsHeparin-binding EGF-like Growth FactorHumansMiceProtein BindingWorkflowADAM17 ProteinAdam17 protein, mouseHeparan Sulfate ProteoglycansHeparin-binding EGF-like Growth FactorADAM17ectodomain sheddingheparan sulphate proteoglycansmetalloproteinasesproteomicssecretome analysis

Identifiers

PMID39318062
PMCPMC11648071

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.